放射性碘难治性甲状腺癌治疗领域的研究热点及趋势可视化分析  

Visualization Analysis of Research Hotspots and Trends in Treatment of Radioactive Iodine Refractory Differentiated Thyroid Carcinoma

作　　者：曾萧贤 张弘[1] ZENG Xiaoxian;ZHANG Hong(Department of Nuclear Medicine,Shenshan Medical Center,Memorial Hospital of Sun Yatsen University,Shanwei 516600,China)

机构地区：[1]中山大学孙逸仙纪念医院深汕中心医院核医学科,汕尾516600

出　　处：《肿瘤防治研究》2025年第2期156-164,共9页Cancer Research on Prevention and Treatment

摘　　要：目的 探讨2004-2024年放射性碘难治性甲状腺癌(RAIR-DTC)治疗领域的相关研究热点及未来发展趋势。方法 从Web of Science中检索2004年1月-2024年5月关于RAIR-DTC治疗领域的文献。采用CiteSpace、VOSviewer、Microsoft Office Excel软件对发文量、国家、机构、作者、关键词和共引网络进行可视化分析及总结。结果 最终纳入了677篇文献。国家和机构共现分析显示美国及美国德克萨斯大学安德森癌症中心在该领域最具生产力和影响力。作者和引文共现分析显示Schlumberger M和Brose MS对相关领域贡献突出。高频关键词和关键词聚类显示酪氨酸激酶抑制剂和疾病预后因素的探究是当前的研究热点。结合关键词突现分析显示通过高质量临床试验提供的可靠数据优化临床获益,实现个体化、精准化治疗管理将成为未来的研究趋势。结论 靶向药物对于RAIR-DTC治疗拥有广阔的应用前景,关注疾病预后的预测因素为医学实践提供了重要指导。Objective To explore research hotspots and future development trends in radioactive iodine refractory differentiated thyroid carcinoma(RAIR-DTC)treatment from 2004 to 2024.Methods Literature on RAIR-DTC treatment published from January 2004 to May 2024 was retrieved from the Web of Science(WOS)database.CiteSpace,VOSviewer,and Microsoft Office Excel were used for visual analysis of publication volume,countries,institutions,authors,keywords,and co-citation networks.Results A total of 677 articles were included in the analysis.National and institutional co-occurrence analysis revealed that the United States,along with the MD Anderson Cancer Center at the University of Texas,was the most productive and influential in this field.Author and citation co-occurrence analysis highlighted the substantial contributions of Schlumberger M and Brose MS to the field.The exploration of high-frequency keywords and keyword clustering indicated tyrosine kinase inhibitors and disease prognostic factors were current research hotspots.Keyword burst analysis suggested that future research trends would focus on optimizing clinical benefits through reliable data provided from high-quality clinical trials and achieving personalized,precise treatment management.Conclusion Targeted drugs hold remarkable potential for RAIR-DTC treatment,and emphasizing predictive factors for disease prognosis offers valuable guidance for medical practice.

关 键 词：放射性碘难治性甲状腺癌 治疗 CITESPACE VOSviewer 文献计量学 

分 类 号：R736.1[医药卫生—肿瘤]